The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. Year to date metric has recorded a gain of 15.94%.However, over the last six months, we can see a stronger performance of -34.92%. Over the last 30 days, the price of LCTX has fallen by 2.00%. And in the last five days, it has surged by 17.46%.
In terms of market performance, Lineage Cell Therapeutics Inc had a fairly uneven. The highest value for the stock in the past year was $1.61 on 03/28/24, and the lowest value was recorded at $0.48 on 12/30/24.
52-week price history of LCTX Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Lineage Cell Therapeutics Inc’s current trading price is -63.81% away from its 52-week high, while its distance from the 52-week low is 21.12%. The stock’s price range during this time has been between $0.48 and $1.61. The trading volume for the Healthcare sector company’s shares reached about 1.33 million for the day, which was lower than the average daily volume of 2.18 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Lineage Cell Therapeutics Inc (LCTX) has experienced a quarterly decline of -33.42% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 128.42M and boasts a workforce of 75 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.7782, with a change in price of -0.2197. Similarly, Lineage Cell Therapeutics Inc recorded 1,517,396 in trading volume during the last 100 days, posting a change of -27.38%.
LCTX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for LCTX stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.02.
LCTX Stock Stochastic Average
Today, Lineage Cell Therapeutics Inc’s raw stochastic average for the past 50 days stands at 20.78%, indicating a decline from the raw stochastic average of the last 20 days, which was 73.09%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 66.93% and 52.37% respectively.
